Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.47 |
| ▸ | BRD2 | P25440 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 12/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977307 | 1.00 | BRD4 (0.47) | BRD4BRD2KCNH2BRD3ALOX5AP | |
| SCHEMBL3656371 | 0.92 | ALOX5AP (0.43) | BRD4BRD2KCNH2BRD3ALOX5AP | |
| SCHEMBL976521 | 0.92 | ALOX5AP (0.43) | BRD4BRD2KCNH2BRD3ALOX5AP | |
| SCHEMBL974874 | 0.89 | ALOX5AP (0.44) | BRD4BRD2KCNH2BRD3ALOX5AP | |
| SCHEMBL974876 | 0.89 | ALOX5AP (0.44) | BRD4BRD2KCNH2BRD3ALOX5AP | |
| SCHEMBL976908 | 0.88 | ALOX5AP (0.42) | BRD4BRD2KCNH2BRD3ALOX5AP | |
| SCHEMBL976910 | 0.88 | ALOX5AP (0.42) | BRD4BRD2KCNH2BRD3ALOX5AP | |
| SCHEMBL978643 | 0.87 | ALOX5AP (0.43) | BRD4BRD2KCNH2BRD3ALOX5AP | |
| SCHEMBL976566 | 0.86 | ALOX5AP (0.41) | BRD4ALOX5APJAK3CREBBP | |
| SCHEMBL976564 | 0.86 | ALOX5AP (0.41) | BRD4ALOX5APJAK3CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2209761-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | Merck Sharp & Dohme Corp. (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009048547-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | PTGIS, PTGS1, LTC4S | BRD4 1514/4885BRD2 1923/4885KCNH2 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.